ID   SK-MEL-93 DX-3
AC   CVCL_5650
AS   CVCL_U903
SY   SK-MEL-93-DX-3; SK-MEL-93 DX3; SK-MEL-93 (DX3); DX-3; DX3; SK-MEL-93(3); SK-MEL-93-3; DX-Mel-3
DR   BTO; BTO_0003988
DR   Cosmic; 721806
DR   Cosmic; 926002
DR   Cosmic; 932703
DR   Cosmic; 933121
DR   KCLB; 80012
DR   Wikidata; Q54954341
RX   PubMed=1716514;
RX   PubMed=2060182;
RX   PubMed=2297053;
RX   PubMed=2886213;
RX   PubMed=2983346;
RX   PubMed=6582512;
RX   PubMed=6744277;
RX   PubMed=6976407;
RX   PubMed=7017212;
RX   PubMed=7780963;
RX   PubMed=9598804;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Heterozygous (PubMed=9598804).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
CC   Omics: Proteomics; 2DE.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5651 ! SK-MEL-93 DX-1
OI   CVCL_5652 ! SK-MEL-93 DX-2
OI   CVCL_A432 ! SK-MEL-93 DX-4
OI   CVCL_A433 ! SK-MEL-93 DX-5
OI   CVCL_A434 ! SK-MEL-93 DX-6
OI   CVCL_A435 ! SK-MEL-93 DX-B
SX   Female
AG   71Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 20
//
RX   PubMed=1716514;
RA   Albino A.P., Davis B.M., Nanus D.M.;
RT   "Induction of growth factor RNA expression in human malignant
RT   melanoma: markers of transformation.";
RL   Cancer Res. 51:4815-4820(1991).
//
RX   PubMed=2060182; DOI=10.1007/BF01753726;
RA   Easty D.J., Hart I.R., Patel K., Seymour C., Yacoub M.H., Domscheit A.,
RA   Gunther S., Postel W., Gorg A., Dunn M.J.;
RT   "Changes in protein expression during melanoma differentiation
RT   determined by computer analysis of 2-D gels.";
RL   Clin. Exp. Metastasis 9:221-230(1991).
//
RX   PubMed=2297053; PMCID=PMC1877453;
RA   Schackert G., Price J.E., Zhang R.-D., Bucana C.D., Itoh K.,
RA   Fidler I.J.;
RT   "Regional growth of different human melanomas as metastases in the
RT   brain of nude mice.";
RL   Am. J. Pathol. 136:95-102(1990).
//
RX   PubMed=2886213;
RA   Dracopoli N.C., Alhadeff B., Houghton A.N., Old L.J.;
RT   "Loss of heterozygosity at autosomal and X-linked loci during tumor
RT   progression in a patient with melanoma.";
RL   Cancer Res. 47:3995-4000(1987).
//
RX   PubMed=2983346; DOI=10.1073/pnas.82.5.1470; PMCID=PMC397284;
RA   Dracopoli N.C., Houghton A.N., Old L.J.;
RT   "Loss of polymorphic restriction fragments in malignant melanoma:
RT   implications for tumor heterogeneity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6744277;
RA   Kozlowski J.M., Fidler I.J., Campbell D., Xu Z.-L., Kaighn M.E.,
RA   Hart I.R.;
RT   "Metastatic behavior of human tumor cell lines grown in the nude
RT   mouse.";
RL   Cancer Res. 44:3522-3529(1984).
//
RX   PubMed=6976407; DOI=10.1084/jem.154.6.1764; PMCID=PMC2186539;
RA   Albino A.P., Lloyd K.O., Houghton A.N., Oettgen H.F., Old L.J.;
RT   "Heterogeneity in surface antigen and glycoprotein expression of cell
RT   lines derived from different melanoma metastases of the same patient.
RT   Implications for the study of tumor antigens.";
RL   J. Exp. Med. 154:1764-1778(1981).
//
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
//
RX   PubMed=7780963;
RA   Easty D.J., Guthrie B.A., Maung K., Farr C.J., Lindberg R.A.,
RA   Toso R.J., Herlyn M., Bennett D.C.;
RT   "Protein B61 as a new growth factor: expression of B61 and
RT   up-regulation of its receptor epithelial cell kinase during melanoma
RT   progression.";
RL   Cancer Res. 55:2528-2532(1995).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//